GlyCLICK® for Therapeutic ADCs

GlyCLICK enables therapeutic ADC development with precise, site-specific conjugation of native IgG – no protein engineering, no delays, no commitment. Available today and ready to use. Whether you’re screening early candidates or preparing for clinical scale-up, GlyCLICK delivers consistent DAR, broad payload compatibility, and a clear path to clinic.
 

GlyCLICK simplifies antibody-drug conjugation with precise, site-specific modification of native IgG – no protein engineering required. It supports your ADC development from early discovery to clinical scale, offering the control, flexibility, and reproducibility you need to move forward with confidence.

1. Reproducible, Site-Specific Conjugation

Achieve a defined DAR 2 on native IgG with homogeneous, reproducible performance and preserved immunoreactivity.

2. Broad Payload and Linker Compatibility

Design with flexibility using a wide range of cytotoxic payloads and linker strategies.

3. Easy Evaluation, Proven Performance

Evaluate the technology immediately with off-the-shelf kits.